Aspirin + Novel Lipoic Acid Against Cancer - Abstract

[JohnHafterson]

Interesting brief abstract on aspirin and lipoic acid nanodrug combination against cancer.

I found while doing a search to see if lipoic acid may limit of some of aspirin's potential side effects.

Supplemental consumer lipoic & aspirin could be an interesting combo.

I assume the novel aspirin lipoic acid combination is for better absorption/distribution/action etc but also be for patent-type purposes instead of plebs using over the counter measures.

https://pubs.acs.org/doi/10.1021/acs.bioconjchem.2c00548

 

[David PS]

Aspirin alone seems to work as well.

An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention​

Abstract​

Chemoprevention refers to the use of natural or synthetic agents to reverse, suppress, or prevent the progression or recurrence of cancer. A large body of preclinical and clinical data suggest the ability of aspirin to prevent precursor lesions and cancers, but much of the clinical data are inferential and based on descriptive epidemiology, case control, and cohort studies or studies designed to answer other questions (e.g., cardiovascular mortality). Multiple pharmacological, clinical, and epidemiologic studies suggest that aspirin can prevent certain cancers but may also cause other effects depending on the tissue or disease and organ site in question. The best-known biological targets of aspirin are cyclooxygenases, which drive a wide variety of functions, including hemostasis, inflammation, and immune modulation. Newly recognized molecular and cellular interactions suggest additional modifiable functional targets, and the existence of consensus molecular cancer subtypes suggests that aspirin may have differential effects based on tumor heterogeneity. This review focuses on new pharmacological developments and innovations in biopharmacology that clarify the potential role of aspirin in cancer chemoprevention.